The Feasibility and Advantages of Subxiphoid Uniportal Video-assisted Thoracoscopic Surgery in Pulmonary Lobectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03051438 |
Recruitment Status : Unknown
Verified May 2018 by Xueying Yang, Shengjing Hospital.
Recruitment status was: Active, not recruiting
First Posted : February 13, 2017
Last Update Posted : May 24, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lobectomy Subxiphoid Uniportal Video-assisted Thoracoscopic Surgery | Procedure: Subxiphoid uniportal VATS Procedure: Three-port VATS | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 86 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | The Feasibility and Advantages of Subxiphoid Uniportal Video-assisted Thoracoscopic Surgery in Pulmonary Lobectomy.A Retrospective Study |
Actual Study Start Date : | January 2016 |
Estimated Primary Completion Date : | June 2018 |
Estimated Study Completion Date : | June 2018 |
Arm | Intervention/treatment |
---|---|
Subxiphoid uniportal VATS
retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
|
Procedure: Subxiphoid uniportal VATS
Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi. |
Three-port VATS
retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
|
Procedure: Three-port VATS
The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi |
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [ Time Frame: 17 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with lung cancer can be undertook the subxiphoid uniportal VATS or three-port VATS
Exclusion Criteria:
- Contraindications in patients with lung cancer

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03051438
China, Liaoning | |
Shengjing Hospital | |
Shenyang, Liaoning, China, 110004 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Xueying Yang, Professor, Shengjing Hospital |
ClinicalTrials.gov Identifier: | NCT03051438 |
Other Study ID Numbers: |
B451-1 |
First Posted: | February 13, 2017 Key Record Dates |
Last Update Posted: | May 24, 2018 |
Last Verified: | May 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |